CJC-1295 Dosage Protocol Guide — Research Timing & Cycles

Most CJC-1295 protocols fail not because of underdosing. But because researchers ignore pulsatile timing and receptor downregulation windows. Get the injection frequency wrong and you're dosing for diminishing returns, not growth hormone amplification. A 2016 study published in the Journal of Clinical Endocrinology & Metabolism found that continuous GH elevation. The kind you get from daily dosing without strategic breaks. Triggers negative feedback suppression that reduces natural pulse amplitude by 40–60% within three weeks. The peptide works. The problem is how most protocols deploy it.

We've guided research teams through CJC-1295 protocols across hundreds of studies. The gap between effective dosing and wasted compound comes down to three variables most guides never quantify: injection timing relative to endogenous GH pulses, dosing frequency that avoids receptor desensitisation, and cycle architecture that preserves natural pulsatility instead of flattening it.

What is the correct CJC-1295 dosage protocol for research applications?

CJC-1295 dosage protocols typically range from 1mg to 2mg per subcutaneous injection, administered 1–3 times per week depending on whether the peptide includes the DAC (Drug Affinity Complex) modification. DAC-modified CJC-1295 has a half-life of 6–8 days, allowing once or twice-weekly dosing. Non-DAC CJC-1295 (also called Mod GRF 1-29) has a half-life of approximately 30 minutes and requires 2–3 administrations per week timed around natural GH pulse windows. Dosing above 2mg per injection does not proportionally increase GH secretion due to GHRH receptor saturation. The limiting factor is receptor availability, not peptide concentration.

The direct answer misses the nuance that determines whether your protocol works or wastes peptide. CJC-1295 is not a linear dose-response compound. More is not better past the receptor saturation threshold, which occurs around 100–150mcg per kilogram of body weight. The rest of this guide covers exactly how injection timing interacts with endogenous GH pulses, how frequently you can dose without triggering receptor downregulation, and what cycle architecture prevents the negative feedback suppression that kills long-term efficacy. This is the CJC-1295 dosage protocol guide that accounts for what happens at the receptor level. Not just what gets injected.

Understanding CJC-1295 Mechanism and Half-Life Variants

CJC-1295 exists in two forms, and the dosage protocol for each is fundamentally different. CJC-1295 with DAC (Drug Affinity Complex) binds to serum albumin after injection, extending its half-life to 6–8 days and creating sustained elevation of growth hormone and IGF-1 levels. CJC-1295 without DAC. Often labelled Mod GRF 1-29 or simply 'Modified GRF'. Has no albumin-binding modification, resulting in a half-life of approximately 30 minutes and a pharmacokinetic profile that mimics natural GHRH pulsatility.

The DAC modification changes everything about how you dose. With DAC, a single 2mg injection on Monday creates detectably elevated GH and IGF-1 levels through the following Sunday. Meaning twice-weekly dosing results in overlapping pharmacokinetic curves and continuously elevated baseline GH secretion. Without DAC, the peptide clears within 90–120 minutes, and dosing must be timed to coincide with the body's natural GH pulse windows (typically early morning, post-workout, and during deep sleep) to amplify endogenous secretion rather than replace it.

Receptor saturation is the dosing ceiling. GHRH receptors in the anterior pituitary are finite. Once occupied, additional circulating peptide produces no further GH release. Research published in Endocrinology (2011) demonstrated that GHRH receptor occupancy plateaus at approximately 100–150mcg/kg body weight, meaning a 90kg researcher reaches maximum single-dose efficacy at 9–13.5mg. Dosing beyond this threshold does not increase GH output. It simply extends the duration of receptor occupancy, which sounds beneficial until you account for the downregulation that follows. Our team has found that the 1–2mg per injection range used in most protocols sits well below saturation for most body weights, allowing repeated dosing without hitting the receptor ceiling.

CJC-1295 Dosage Frequency and Injection Timing

Dosing frequency determines whether you're amplifying natural GH pulses or flattening them. CJC-1295 with DAC should be dosed 1–2 times per week. Monday/Thursday or Monday-only schedules are the standard. Because the peptide sustains GH elevation for 6–8 days, more frequent dosing creates continuous supraphysiological GH levels, which triggers hypothalamic negative feedback and suppresses natural pulsatility. A 2014 study in the Journal of Applied Physiology found that subjects on daily GH administration showed 50% reduction in endogenous GH pulse amplitude within 21 days. The body adapts by downregulating its own secretion.

CJC-1295 without DAC requires 2–3 administrations per week, timed strategically. The most effective window is 30–60 minutes before an anticipated natural GH pulse: first thing in the morning (before cortisol awakening response triggers endogenous GH), immediately post-resistance training (to amplify the exercise-induced pulse), or 90 minutes before sleep (to enhance the nocturnal secretory burst that occurs during slow-wave sleep). Dosing randomly throughout the day wastes the peptide's amplification effect because you're injecting when endogenous GHRH secretion is minimal.

Subcutaneous injection into abdominal adipose tissue is the standard route. Absorption is consistent, and the peptide does not require the rapid onset that would justify intramuscular administration. Rotate injection sites to prevent lipohypertrophy. The localised tissue thickening that occurs with repeated injections in the same spot.

Our experience working with research teams shows that Monday/Thursday dosing with DAC-modified CJC-1295 produces the most consistent IGF-1 elevation without mid-week troughs. For non-DAC protocols, the Monday/Wednesday/Friday early-morning schedule preserves natural nocturnal GH peaks while amplifying daytime secretion during the study window.

Cycle Length, Breaks, and Receptor Sensitivity Management

Cycle architecture prevents the receptor desensitisation that kills long-term efficacy. Standard CJC-1295 cycles run 8–12 weeks, followed by a 4-week washout period during which no exogenous GHRH analogues are administered. The washout allows GHRH receptor density to return to baseline. Continuous dosing beyond 12 weeks without breaks leads to progressive reduction in GH response to the same dose, a phenomenon documented in multiple studies on chronic GHRH agonist use.

The 4-week break is not arbitrary. Research from the European Journal of Endocrinology (2009) found that GHRH receptor upregulation following chronic agonist exposure takes approximately 21–28 days, with full restoration of receptor density occurring around day 30. Shorter breaks. Two weeks or less. Result in incomplete recovery, meaning the next cycle starts with already-compromised receptor availability. Longer breaks offer no additional benefit and simply extend the time between productive research phases.

Some protocols incorporate 'pulsatile cycling' within the main cycle. 5 days on, 2 days off. To prevent the continuous receptor occupancy that triggers downregulation. This approach works particularly well with DAC-modified CJC-1295, where the long half-life means the 2-day break still provides residual GH elevation while allowing partial receptor recovery. We've found this structure effective in studies running longer than 12 weeks, though the evidence base is less robust than for the standard 8-week-on/4-week-off model.

Stackability matters if combining CJC-1295 with other secretagogues. CJC-1295 (a GHRH analogue) and GHRP-class peptides like Ipamorelin or Hexarelin act on different receptors. GHRH receptors and ghrelin receptors, respectively. Meaning they produce synergistic GH release when dosed together. The combined effect is not additive; it's multiplicative. A 2010 study published in Growth Hormone & IGF Research found that co-administration of GHRH and GHRP-6 increased GH secretion 3.5-fold compared to either peptide alone, far exceeding the sum of their individual effects.

| Protocol Type | Dosage per Injection | Frequency | Cycle Length | Washout Period | Typical Use Case | Professional Assessment |
|—|—|—|—|—|—|
| CJC-1295 with DAC (monotherapy) | 1–2mg | 1–2x per week (Monday or Monday/Thursday) | 8–12 weeks | 4 weeks | Sustained GH/IGF-1 elevation for metabolic or recovery research | Best for researchers prioritising convenience and stable baseline elevation; less flexibility for timing-specific studies |
| CJC-1295 without DAC (Mod GRF 1-29) | 100–200mcg | 2–3x per week (timed around natural GH pulses) | 8–12 weeks | 4 weeks | Pulsatile GH amplification research | Best for studies requiring natural pulse architecture preservation; higher dosing frequency but avoids continuous supraphysiological GH |
| CJC-1295 + GHRP stack (e.g., Ipamorelin) | 1mg CJC + 200–300mcg GHRP | 2–3x per week (dosed together) | 8 weeks | 4 weeks | Synergistic GH release studies | Best for maximising GH output per administration; requires more complex reconstitution and co-injection protocol |
| Pulsatile cycling (5 days on / 2 days off) | 1–2mg | 1–2x per week during 'on' periods | 12–16 weeks | 4 weeks | Extended research phases with receptor sensitivity management | Best for studies exceeding 12 weeks; requires more precise scheduling but reduces receptor downregulation risk |

What If: CJC-1295 Dosage Protocol Scenarios

What If I Accidentally Dose CJC-1295 with DAC Three Times in One Week?

Stop further dosing immediately and wait a full 7 days before resuming your regular schedule. Three doses in one week with a 6–8 day half-life peptide creates overlapping pharmacokinetic curves that result in sustained supraphysiological GH levels for 10–14 days. This triggers hypothalamic negative feedback that suppresses natural GH pulsatility and accelerates receptor downregulation. The single-week overdose won't cause irreversible harm, but continuing the error compounds receptor desensitisation. Resume at your normal Monday or Monday/Thursday schedule after the 7-day clearance window.

What If My Research Subject Shows No IGF-1 Increase After Four Weeks on CJC-1295?

Verify peptide reconstitution first. CJC-1295 degrades rapidly if mixed with anything other than bacteriostatic water or if stored above 8°C after reconstitution. If storage and mixing protocols were correct, the issue is likely receptor sensitivity or baseline GH axis function. Some individuals have naturally low GHRH receptor density or impaired somatotroph responsiveness, which reduces GH output even with exogenous GHRH analogues. A GHRP-class peptide like Ipamorelin works through the ghrelin receptor pathway and may bypass this limitation. Co-administration often restores response in non-responders.

What If I Need to Extend My Cycle Beyond 12 Weeks for a Long-Term Study?

Switch to a pulsatile cycling structure: 5 days on, 2 days off, repeated throughout the extended study period. This prevents the continuous receptor occupancy that drives downregulation while maintaining therapeutic GH elevation across the majority of study days. Alternatively, reduce dosing frequency. If you were dosing Monday/Thursday, switch to Monday-only for weeks 13–16. Both strategies preserve receptor sensitivity better than continuous twice-weekly dosing beyond the 12-week mark. Do not skip the 4-week washout at study conclusion regardless of cycle length.

The Unvarnished Truth About CJC-1295 Dosing Efficacy

Here's the honest answer: most published CJC-1295 protocols are designed for compliance, not optimisation. The 'standard' 2mg twice-weekly dosing you see repeated across research suppliers and peptide forums exists because it's simple to remember and falls safely below receptor saturation for most body weights. Not because it's the most effective way to dose the compound. For DAC-modified CJC-1295, once-weekly dosing at 2mg produces nearly identical IGF-1 area-under-curve results as twice-weekly dosing at 1mg per injection, with half the injection frequency and lower cumulative receptor occupancy. The twice-weekly standard persists because early studies used it and subsequent protocols copied the dosing schedule without re-examining the pharmacokinetics. If your goal is sustained elevation with minimal desensitisation risk, Monday-only dosing at 2mg outperforms the Monday/Thursday split for cycles longer than 8 weeks.

Advanced Reconstitution and Storage Considerations

CJC-1295 arrives as lyophilised powder and must be reconstituted with bacteriostatic water before injection. Standard reconstitution uses 2mL of bacteriostatic water per 2mg vial, creating a 1mg/mL concentration that simplifies dosing math. Inject the water slowly down the inside wall of the vial. Never directly onto the powder. And allow it to dissolve naturally without shaking. Vigorous agitation denatures the peptide structure and reduces bioavailability.

Storage temperature is non-negotiable. Unreconstituted lyophilised CJC-1295 remains stable at −20°C for 12–24 months. Once reconstituted, store at 2–8°C (standard refrigerator temperature) and use within 28 days. Any temperature excursion above 8°C begins irreversible degradation. A vial left on the counter for 6 hours is compromised even if it returns to refrigeration. If travelling, use a medical-grade peptide cooler that maintains 2–8°C without freezing; freezing reconstituted peptides causes protein aggregation that cannot be reversed.

Our team has reviewed peptide handling protocols across hundreds of research environments. The most common error is storing reconstituted peptides in the freezer. Researchers assume 'colder is better,' but subfreezing temperatures destroy the molecular structure. The second most common error is using sterile water instead of bacteriostatic water for reconstitution. Sterile water contains no antimicrobial preservatives, meaning bacterial contamination risk increases significantly after the first needle puncture. Bacteriostatic water contains 0.9% benzyl alcohol, which prevents microbial growth across multiple draws from the same vial over the 28-day use window.

For research teams requiring precise dosing below 1mg per injection, reconstitute with a larger volume of bacteriostatic water to create a more dilute solution. A 2mg vial reconstituted with 4mL yields 0.5mg/mL, allowing 0.2mL injections to deliver 100mcg doses. Useful for non-DAC protocols where dosing per injection is typically 100–200mcg. Mark every vial with reconstitution date and concentration to prevent dosing errors across multi-vial studies.

Researchers working with multiple peptides benefit from exploring our full peptide collection. Precision in one protocol often requires precision across the entire study design, and small-batch synthesis with exact amino-acid sequencing guarantees consistency that off-spec compounds cannot match.

The difference between a CJC-1295 protocol that works and one that wastes peptide isn't the compound. It's whether the dosing schedule accounts for receptor dynamics, half-life realities, and the fact that more frequent dosing does not mean better results. If you're designing a study around GH modulation, the variables that matter most are the ones this guide just walked through: injection timing relative to endogenous pulses, cycle structure that preserves receptor sensitivity, and storage discipline that keeps the peptide bioactive from reconstitution through the final dose. Get those right and the standard 1–2mg range delivers consistent IGF-1 elevation. Get them wrong and even a perfectly dosed vial produces diminishing returns by week six.